---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-066791"
form_type: "8-K/A"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-03-10T23:59:59+00:00"
generated_at: "2026-06-18T05:57:38.894945+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine reports Q4 net loss $39.3M, FY2022 net loss $121.8M; nominates PM359 for CGD

## Summary
- Q4 2022 net loss $39.3M improved from $62.9M in Q4 2021; FY2022 net loss $121.8M vs $165.4M prior year.
- R&D expenses $29.1M in Q4 and $86.7M for FY2022; G&A $9.6M and $29.8M, respectively.
- Cash, short-term investments $293.9M as of Dec 31, 2022, up from $269.6M year-end 2021, boosted by $180.2M IPO net proceeds.
- Nominated PM359 as first development candidate for chronic granulomatous disease (CGD); IND-enabling studies planned for 2023.
- Preclinical proof-of-concept data for FRDA, CF, and Wilson's disease; first IND filing expected as early as 2024.

## SEC filing metadata
- accession: 0001193125-23-066791
- form_type: 8-K/A
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/0001193125-23-066791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/d342589d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-066791
- JSON: https://secwatch.observer/filing/0001193125-23-066791.json
- Plain text: https://secwatch.observer/filing/0001193125-23-066791.txt

## Key facts
- Earnings Releases
  Prime Medicine, Inc. reported the year ended December 31, 2022 results: net income Net loss was $121.8 million for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Net income: Net loss was $121.8 million for the year ended December 31, 2022
  - Result: reported results
  source text: Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/0001193125-23-066791-index.htm
- Earnings Releases
  Prime Medicine, Inc. reported the fourth quarter of 2022 results: net income Net loss was $39.3 million for the fourth quarter of 2022.
  - Period: the fourth quarter of 2022
  - Net income: Net loss was $39.3 million for the fourth quarter of 2022
  - Result: reported results
  source text: Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/0001193125-23-066791-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.